These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12853545)

  • 1. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers.
    Newhouse MT; Hirst PH; Duddu SP; Walter YH; Tarara TE; Clark AR; Weers JG
    Chest; 2003 Jul; 124(1):360-6. PubMed ID: 12853545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative lung distribution of radiolabeled tobramycin between nebulized and intravenous administration in a mechanically-ventilated ovine model, an observational study.
    Dhanani JA; Goodman S; Ahern B; Cohen J; Fraser JF; Barnett A; Diab S; Bhatt M; Roberts JA
    Int J Antimicrob Agents; 2021 Feb; 57(2):106232. PubMed ID: 33232733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
    Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
    Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder.
    Duddu SP; Sisk SA; Walter YH; Tarara TE; Trimble KR; Clark AR; Eldon MA; Elton RC; Pickford M; Hirst PH; Newman SP; Weers JG
    Pharm Res; 2002 May; 19(5):689-95. PubMed ID: 12069174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
    Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
    J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
    Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
    J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
    Miller DP; Tan T; Tarara TE; Nakamura J; Malcolmson RJ; Weers JG
    Mol Pharm; 2015 Aug; 12(8):2582-93. PubMed ID: 26052676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis.
    Zhu B; Padroni M; Colombo G; Phillips G; Crapper J; Young PM; Traini D
    Int J Pharm; 2016 Dec; 514(2):392-398. PubMed ID: 27063852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients.
    Pilcer G; Goole J; Van Gansbeke B; Blocklet D; Knoop C; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2008 Feb; 68(2):413-21. PubMed ID: 17574400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
    Geller DE; Rosenfeld M; Waltz DA; Wilmott RW;
    Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry Powder Inhaler Delivery of Tobramycin in In Vitro Models of Tracheostomized Children.
    Wee WB; Tavernini S; Martin AR; Amirav I; Majaesic C; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):64-70. PubMed ID: 27563934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model.
    Dhanani JA; Diab S; Chaudhary J; Cohen J; Parker SL; Wallis SC; Boidin C; Barnett A; Chew M; Roberts JA; Fraser JF
    Anesthesiology; 2019 Aug; 131(2):344-355. PubMed ID: 31107274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
    Geller DE; Weers J; Heuerding S
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):175-82. PubMed ID: 21395432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition.
    Coates AL; Dinh L; MacNeish CF; Rollin T; Gagnon S; Ho SL; Lands LC
    J Aerosol Med; 2000; 13(3):169-78. PubMed ID: 11066020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique.
    Warren S; Taylor G; Smith J; Buck H; Parry-Billings M
    J Aerosol Med; 2002; 15(1):15-25. PubMed ID: 12006142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times.
    Coates AL; Green M; Leung K; Louca E; Tservistas M; Chan J; Ribeiro N; Charron M
    J Aerosol Med; 2007; 20(3):320-30. PubMed ID: 17894538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nebulizer configuration on delivery of aerosolized tobramycin.
    O'Riordan TG; Amram JC
    J Aerosol Med; 1997; 10(1):13-23. PubMed ID: 10166359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.